[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.204.173.45. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Comment & Response
October 2017

Levodopa and Parkinson Disease—Myths Revisited—Reply

Author Affiliations
  • 1Neurology, University of Cincinnati, Cincinnati, Ohio
  • 2The Morton and Gloria Shulman Movement Disorders Centre, Toronto Western Hospital, Toronto, Ontario, Canada
JAMA Neurol. 2017;74(10):1270-1271. doi:10.1001/jamaneurol.2017.2563

In Reply We appreciate the attention from Lim and colleagues to our Viewpoint1 on common myths in the use of levodopa in Parkinson disease (PD). We clarified in our article that the subtitle “When Clinical Trials Misinform Clinical Practice” should mean, if character counts had no limits, “when the interpretation of clinical trials misinform clinical practice.” We do not disagree on this point.

×